Mike Clark's Research Interests:

Commercial Applications

On another page you can find a summary of my academic research interests within the University of Cambridge. Several of the projects have given rise to commercial intellectual property rights (IPR), these are mainly specific antibodies or methods of how to make or use them. Most of these IPRs have been assigned or licensed through the University's Wolfson Industrial Liaison, or Technology Transfer, Offices, now known as Cambridge Enterprise ( www.enterprise.cam.ac.uk ). Listed below are links to those projects which are in commercial development.

Many of these projects have been the result of collaborative research and in some projects I may not have been the principle investigator. Also please note that I may not have any current involvement with or knowledge of these projects, or products, other than through my legal rights as an inventor, or more often, co-inventor of the initial IPR. Please direct all enquiries related to the projects or products to the appropriate companies to which the products are assigned or licensed, and for which the company links are given below.

Antibodies and IPR in commercial development

CD52 - Antibody CAMPATH (Alemtuzumab)
A humanised antibody (alemtuzumab) to the CD52 antigen on human lymphocytes.
Modified Fc Regions - delta a,b and c modifications of IgG1, 2 and 4
Human antibody Fc regions with altered binding affinity to human Fc-Receptors and complement for use in the construction of recombinant antibodies and fusion proteins for therapy. This technology is covered by patents held by the Cambridge Enterprise and is available for licensing. We are still actively pursuing academic research projects associated with this IPR and we have also signed several commercial licenses for use of the constant regions.
Modified Fc Regions - delta d, and e modifications of human IgG
Human antibody Fc regions with altered binding affinity to human Fc-Receptors and giving rise to enhanced ADCC, for use in the construction of recombinant antibodies and fusion proteins for therapy. This technology is covered by patents held by Cambridge Enterprise and licensed to Xencor.
CD3 - Antibody TRX4
A humanised aglycosylated antibody to the CD3 antigen on T-lymphocytes.
CD4 - Methods of use of antibody TRX1
Use of humanised CD4 antibody to induce immunological tolerance
VAP-1 - Antibody HuVAP
An antibody to the VAP-1 antigen with a modified human IgG2 Fc region.
CAMPATH idiotype - Antibody YID13.9
A rat antibody to the idiotype of CAMPATH of use in diagnostic tests.
Framework Grafting - A method to produce therapeutic human antibodies
A patented general method to produce therapeutic human antibodies by grafting of framework regions.
HPA-1a Typing assay
A diagnostic typing assay for HPA-1a making use of a recombinant human IgG1 antibody
CD18 - Antibody MLN01
A humanised antibody to the CD18 antigen (beta subunit of integrins) on human leukosites for inhibition of migration.
NS0 - Non-producing mouse placmacytoma cell line
This is a mouse plasmacytoma cell line that is used for making hybridomas and expression of recombinant proteins. I was one of the discoverers of this cell line during my PhD studies with César Milstein at the MRC LMB
A separate listing of Mike Clark's academic research interests within the University of Cambridge is available.
© 8th September 2005, Mike Clark, email mrc7@cam.ac.uk